Last reviewed · How we verify
NCT07085195
A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
EARLY_PHASE1 trial testing gene therapy in Parkinson Disease (PD) in 6 participants. Not yet recruiting.
30 December 2025
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 August 2025 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- gene therapy — full drug profile →
- clozapine (CLOZAPINE) — full drug profile →
Conditions studied
- Parkinson Disease (PD) — all drugs for Parkinson Disease (PD) →
- Gene Therapy — all drugs for Gene Therapy →
- Safety and Efficacy — all drugs for Safety and Efficacy →
- Clozapine — all drugs for Clozapine →
Sponsor
Ruijin Hospital
Who can join
Adults 40 to 65, any sex, with Parkinson Disease (PD) or Gene Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose a gene therapy strategy using chemical genetic inhibition to intervene in the abnormal activity of the subthalamic nucleus in Parkinson's disease. The investigators design and construct a highly efficient therapeutic injection STP-001 (first drug), through the efficient adeno-associated virus capsid (AAV), neuronal promoter (hSyn), and chemical genetic effector element (hM4Di), and accurately inject the drug into the bilateral subthalamic nucleus, the core pathological nucleus of Parkinson's disease, through stereotactic technology. Combined with a very low dose of clozapine (the second drug), the abnormal activity of the subthalamic nucleus is precisely intervened to improve the core motor symptoms of Parkinson's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07085195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of gene therapy
Trials testing the same drug.
- NCT07364357 — A Phase I Study of CREPT-618 in Locally Advanced HCC · Phase 1 · recruiting
- NCT06983158 — A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy · Phase 1, PHASE2 · suspended
- NCT01395641 — A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC · Phase 1, PHASE2 · completed
Other recruiting trials for Parkinson Disease (PD)
Currently open trials in the same condition.
- NCT07176286 — 18F-mFBG Cardiac Uptake With Lewy Body Dementia · Phase 2 · recruiting
- NCT07495462 — Effect of Motor Imagery Added to Rehabilitation on Balance and Kinesiophobia in Patients With Parkinson's Disease · NA · recruiting
- NCT07308795 — The Ultrasonographic Evaluation of Abdominal Accessory Respiratory Muscle Thickness in Patients With Parkinson's Disease · recruiting
- NCT07302386 — Exercise Management in Parkinson's Disease · NA · recruiting
- NCT07157345 — Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease · Phase 1 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07085195 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 25 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07085195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing